As­traZeneca grabs PhI­II AT­TR drug from Io­n­is — in­fus­ing $200M cash in­to strug­gling part­ner

As­traZeneca is pluck­ing an­oth­er an­ti­sense drug out of Io­n­is’ pro­lif­ic pipeline.

Pay­ing $200 mil­lion in cash, As­traZeneca has inked a de­vel­op­ment and com­mer­cial­iza­tion deal around eplon­ter­sen — the Phase III TTR amy­loi­do­sis drug for­mer­ly known as IO­N­IS-TTR-LRX. On top of the up­front and $485 mil­lion worth of con­di­tion­al pay­ments to fol­low reg­u­la­to­ry ap­provals, the phar­ma gi­ant is promis­ing $2.9 bil­lion in sales-re­lat­ed mile­stones should the drug reach megablock­buster sta­tus, plus roy­al­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER